ACADIA Pharmaceuticals Inc.

15.74-0.4100-2.54%Vol 1.35M1Y Perf -11.89%
Aug 11th, 2022 16:00 DELAYED
BID14.80 ASK16.78
Open16.11 Previous Close16.15
Pre-Market- After-Market15.74
 - -  - -%
Target Price
24.12 
Analyst Rating
Moderate Buy 2.29
Potential %
53.24 
Finscreener Ranking
★+     43.89
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.15
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     47.64
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
22.13 
Earnings Rating
Neutral
Market Cap2.55B 
Earnings Date
8th Aug 2022
Alpha-0.00 Standard Deviation0.16
Beta0.72 

Today's Price Range

15.5616.28

52W Range

12.2428.06

5 Year PE Ratio Range

-18.80-14.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
-4.26%
1 Month
1.35%
3 Months
-1.81%
6 Months
-39.34%
1 Year
-11.89%
3 Years
-47.04%
5 Years
-49.57%
10 Years
889.94%

TickerPriceChg.Chg.%
ACAD15.74-0.4100-2.54
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
96.50
-43.90
-43.30
-101.10
-46.65
RevenueValueIndustryS&P 500US Markets
377.84M
2.34
22.93
56.36
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.25-0.2116.00
Q01 2022-0.49-0.70-42.86
Q04 2021-0.24-0.27-12.50
Q03 2021-0.27-0.0966.67
Q02 2021-0.30-0.2710.00
Q01 2021-0.53-0.4220.75
Q04 2020-0.48-0.4212.50
Q03 2020-0.38-0.54-42.11
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2510.71Positive
9/2022 QR-0.2122.22Positive
12/2022 FY-1.40-8.53Negative
12/2023 FY-0.80-19.40Negative
Next Report Date-
Estimated EPS Next Report-0.25
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume1.35M
Shares Outstanding161.84K
Shares Float119.24M
Trades Count14.69K
Dollar Volume21.42M
Avg. Volume2.30M
Avg. Weekly Volume2.49M
Avg. Monthly Volume1.78M
Avg. Quarterly Volume2.64M

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 15.74 per share at the end of the most recent trading day (a -2.54% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 2.55B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.

The one-year performance of ACADIA Pharmaceuticals Inc. stock is -11.89%, while year-to-date (YTD) performance is -32.56%. ACAD stock has a five-year performance of -49.57%. Its 52-week range is between 12.24 and 28.055, which gives ACAD stock a 52-week price range ratio of 22.13%

ACADIA Pharmaceuticals Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 5.55, a price-to-sale (PS) ratio of 6.43, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.41%, a ROC of -37.11% and a ROE of -43.62%. The company’s profit margin is -46.65%, its EBITDA margin is -43.30%, and its revenue ttm is $377.84 Million , which makes it $2.34 revenue per share.

Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Moderate Buy (2.29), with a target price of $24.12, which is +53.24% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ACADIA Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.99, CCI20 : 115.74, Chaikin Money Flow : 0.03, MACD : 0.14, Money Flow Index : 65.92, ROC : 13.49, RSI : 45.60, STOCH (14,3) : 74.13, STOCH RSI : 0.76, UO : 62.16, Williams %R : -25.87), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $0), Austin D. Kim (Sold 3 606 shares of value $79 939 ), Brendan P. Teehan (Option Excercise at a value of $0), Brendan P. Teehan (Sold 1 562 shares of value $33 671 ), Elizabeth Garofalo (Option Excercise at a value of $0), James K. Kihara (Option Excercise at a value of $0), James K. Kihara (Sold 1 384 shares of value $36 270 ), Mark Schneyer (Option Excercise at a value of $0), Mark Schneyer (Sold 553 shares of value $13 161 ), Srdjan Stankovic (Option Excercise at a value of $0), Srdjan Stankovic (Sold 10 444 shares of value $209 042 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 16 092 shares of value $330 463 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (35.29 %)
7 (41.18 %)
8 (44.44 %)
Moderate Buy
1 (5.88 %)
1 (5.88 %)
1 (5.56 %)
Hold
9 (52.94 %)
8 (47.06 %)
9 (50.00 %)
Moderate Sell
1 (5.88 %)
1 (5.88 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.29
Moderate Buy
2.18
Moderate Buy
2.06

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

CEO: Stephen R. Davis

Telephone: +1 858 558-2871

Address: 12830 El Camino Real, San Diego 92130, CA, US

Number of employees: 580

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

55%45%

TipRanks News for ACAD

Tue, 09 Aug 2022 04:45 GMT ACADIA Pharmaceuticals (ACAD) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Mon, 11 Jul 2022 12:39 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Sat, 09 Jul 2022 01:45 GMT Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), BioCryst (BCRX) and Cigna (CI)

- TipRanks. All rights reserved.

Tue, 21 Jun 2022 12:26 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Thu, 16 Jun 2022 14:22 GMT Why Did Acadia Pharmaceuticals Shares Gain 15%

- TipRanks. All rights reserved.

Wed, 15 Jun 2022 15:15 GMT Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Boston Scientific (BSX)

- TipRanks. All rights reserved.

Wed, 18 May 2022 13:24 GMT ACADIA Pharmaceuticals: No Upturn in Sight

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:22 GMT ACADIA Pharmaceuticals (ACAD) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Thu, 05 May 2022 10:29 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Sun, 01 May 2022 16:35 GMT Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Compugen (CGEN)

- TipRanks. All rights reserved.

Tue, 19 Apr 2022 10:05 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Needham

- TipRanks. All rights reserved.

Tue, 19 Apr 2022 04:25 GMT Analysts Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), CTI BioPharma (CTIC)

- TipRanks. All rights reserved.

Sat, 09 Apr 2022 01:50 GMT RBC Capital Believes ACADIA Pharmaceuticals (ACAD) Still Has Room to Grow

- TipRanks. All rights reserved.

Mon, 04 Apr 2022 10:55 GMT ACADIA Pharmaceuticals (ACAD) Gets a Hold Rating from Needham

- TipRanks. All rights reserved.

Wed, 09 Mar 2022 20:40 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Berenberg Bank

- TipRanks. All rights reserved.

Wed, 09 Mar 2022 14:35 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and C4 Therapeutics (CCCC)

- TipRanks. All rights reserved.

Mon, 07 Mar 2022 16:42 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Goldman Sachs

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 15:25 GMT Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Irhythm Technologies (IRTC)

- TipRanks. All rights reserved.

News

Stocktwits